Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05627232 | Tazemetostat and Palbociclib With CPX-351for R/R AML | recruiting | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06626633 |
| 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML |
| suspended |
| Phase 1 |
| 6 |
| University of Maryland, BaltimoreOTHER |
| 1 |
| Mar 12, 2026 |
| clinicaltrials |
| NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia(GRACE) | not yet recruiting | Phase 1 / Phase 2 | 50 | University of ManchesterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05123365 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 27 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05672147 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06543381 | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 26 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | recruiting | Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03772925 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia(FHD-286) | recruiting | Phase 1 | 33 | Montefiore Medical CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07441980 | A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | recruiting | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05580601 | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432100 | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 20 | Mingfeng ZhaoOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT04964505 | Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | terminated | Phase 1 | 16 | Brian JonasOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT00544466 | Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | active not recruiting | Phase 1 / Phase 2 | 75 | City of Hope Medical CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04620681 | CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML | completed | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03467386 | Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia | suspended | Phase 1 | 56 | City of Hope Medical CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04328714 | Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease | terminated | Phase 1 | 4 | Edwin HorwitzOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06284460 | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06325748 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | active not recruiting | Phase 1 | 21 | Senti BiosciencesINDUSTRY | 2 | Feb 12, 2026 | clinicaltrials |
| NCT05654779 | CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 4 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05987696 | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | completed | Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06950034 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | recruiting | Phase 1 | 105 | Solu Therapeutics, IncINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07130695 | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | recruiting | Phase 1 | 15 | Virginia Commonwealth UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | recruiting | Phase 1 / Phase 2 | 31 | Jacqueline Garcia, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07321626 | Romiplostim N01 for Platelet Recovery After Haploidentical HSCT | recruiting | Phase 1 | 130 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of Colorado, DenverOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07370064 | Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia(AML CAR-T) | not yet recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT04139434 | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML | completed | Phase 1 | 32 | Newave Pharmaceutical IncINDUSTRY | 2 | Jan 23, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04230265 | Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies | terminated | Phase 1 | 32 | AvenCell Europe GmbHINDUSTRY | 2 | Jan 22, 2026 | clinicaltrials |
| NCT05001828 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | active not recruiting | Phase 1 | 38 | Polaris GroupINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | recruiting | Phase 1 | 60 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML(AML) | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Jan 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2026source: clinicaltrials